Then, the feasibility of using CDKN2A SCND as a biomarker for predicting hematogenous metastasis of GCs was further validated among 174 patients with baseline pN0M0 GC enrolled in the independent prospective study cohort (27). Here, CDKN2A is linked to gastric cancer.